Theravance Biopharma (TBPH) Other Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has reported Other Accumulated Expenses for 14 consecutive years, with $988000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 52.29% year-over-year to $988000.0; the TTM figure through Mar 2026 stood at $988000.0 (down 52.29% YoY), while the FY2025 annual figure was $1.5 million, down 32.93% from the prior year.
• Other Accumulated Expenses declined to $988000.0 in Q1 2026 per TBPH's latest filing, from $1.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.3 million in Q2 2022 and bottomed at $142000.0 in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $1.3 million in 2025.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses plunged 92.24% — and 2023, when it soared 963.38%.
• Theravance Biopharma's Other Accumulated Expenses stood at $1.1 million in 2022, then rose by 8.67% to $1.2 million in 2023, then soared by 78.4% to $2.2 million in 2024, then slumped by 32.93% to $1.5 million in 2025, then plunged by 33.47% to $988000.0 in 2026.
• Business Quant data shows TBPH's Other Accumulated Expenses at $988000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.